RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
8.430 USD   +3.56%
06/22Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintains Buy Rating
MT
06/21RECURSION PHARMACEUTICALS : Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference - Form 8-K
PU
06/21RECURSION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RECURSION PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

01/10/2022 | 06:23am EDT

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, Recursion Pharmaceuticals, Inc. released an updated investor presentation. The investor presentation will be used at the JP Morgan Healthcare meeting and from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 7.01 on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits



Exhibit No.       Description

99.1                Investor presentation of Recursion Pharmaceuticals, Inc. dated
                  January 10, 2022.

104               Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about RECURSION PHARMACEUTICALS, INC.
06/22Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintai..
MT
06/21RECURSION PHARMACEUTICALS : Announces Initiation of Phase 2/3 Trial for the Treatment of N..
PU
06/21RECURSION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
06/20Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meni..
PR
06/20Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meni..
CI
06/16RECURSION PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (for..
AQ
06/09RECURSION PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/09Recursion Pharmaceuticals, Inc. Announces Executive Changes
CI
06/02Recursion to Participate in Upcoming Investor Conferences
PR
05/24Goldman Sachs Lowers Recursion Pharmaceuticals' Price Target to $7 From $9, Neutral Rat..
MT
More news
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
More recommendations